Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Dermatologic 3Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1

Interventions

venetoclax 308Cyclophosphamide 231Cytarabine 201Azacitidine 191fludarabine 181Specimen Handling 136Biopsy 103fludarabine phosphate 97Methotrexate 82Rituximab 79Daunorubicin 77Dexamethasone 76Vincristine 69Whole-Body Irradiation 64Mycophenolic Acid 59Decitabine 58Tacrolimus 55Etoposide 53ibrutinib 52blinatumomab 51Granulocyte Colony-Stimulating Factor 51obinutuzumab 50Busulfan 50Prednisone 49Melphalan 48acalabrutinib 47Injections 46Stem Cell Transplantation 45Idarubicin 45Magnetic Resonance Spectroscopy 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
vedolizumab × Other hematologic neoplasm × 1 year × Clear all
NCT06815003 2025-06-27

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

Phase 2 Recruiting
35 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡